{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T23:04:53Z","timestamp":1789686293660,"version":"4.0.1"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":80,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-026-13857-8","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T04:35:58Z","timestamp":1782794158000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dynamics of spatiotemporal pharmacological models for hepatitis B virus infection under lamivudine and pegylated interferon alfa-2b therapies"],"prefix":"10.1186","volume":"26","author":[{"given":"Boris Rosmes","family":"Tchioffo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Mvogo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice Ele","family":"Abiama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"issue":"6","key":"13857_CR1","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1099\/vir.0.81920-0","volume":"87","author":"A Bertoletti","year":"2006","unstructured":"Bertoletti A, Gehring AJ. The immune response during hepatitis b virus infection. J Gener Virol. 2006;87(6):1439\u201349. https:\/\/doi.org\/10.1099\/vir.0.81920-0.","journal-title":"J Gener Virol"},{"issue":"2","key":"13857_CR2","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/hep.1840030201","volume":"3","author":"RP Beasley","year":"1983","unstructured":"Beasley RP, Hwang L-Y, Stevens CE, Lin C-C, Hsieh F-J, Wang K-Y, et al. Efficacy of hepatitis B immune globulin for prevention of perinatal transmission of the hepatitis B virus carrier state: final report of a randomized double\u2013blind, placebo\u2013controlled trial. Hepatology. 1983;3(2):135\u201341. https:\/\/doi.org\/10.1002\/hep.1840030201.","journal-title":"Hepatology"},{"issue":"5","key":"13857_CR3","doi-asserted-by":"publisher","first-page":"613","DOI":"10.7326\/0003-4819-101-5-613","volume":"101","author":"JI Weissberg","year":"1984","unstructured":"Weissberg JI, Andres LL, Smith CI, Weick S, Nichols JE, Garcia G, et al. Survival in chronic hepatitis b: an analysis of 379 patients. Ann Intern Med. 1984;101(5):613\u201316. https:\/\/doi.org\/10.7326\/0003-4819-101-5-613.","journal-title":"Ann Intern Med"},{"key":"13857_CR4","doi-asserted-by":"crossref","unstructured":"Hochman JA, Balistreri WF. Acute and chronic viral hepatitis. 2007.","DOI":"10.1017\/CBO9780511547409.019"},{"issue":"3","key":"13857_CR5","doi-asserted-by":"publisher","first-page":"288","DOI":"10.3390\/vaccines12030288","volume":"12","author":"SA Al-Busafi","year":"2024","unstructured":"Al-Busafi SA, Alwassief A. Global perspectives on the hepatitis b vaccination: challenges, achievements, and the road to elimination by 2030. Nato Adv Sci Inst Se. 2024;12(3):288. https:\/\/doi.org\/10.3390\/vaccines12030288.","journal-title":"Nato Adv Sci Inst Se"},{"key":"13857_CR6","doi-asserted-by":"publisher","unstructured":"Herrscher C, Roingeard P, Blanchard E. Hepatitis b virus entry into cells. Cells. 2020;9(6):1486. https:\/\/doi.org\/10.3390\/cells9061486.","DOI":"10.3390\/cells9061486"},{"key":"13857_CR7","doi-asserted-by":"publisher","first-page":"435","DOI":"10.2147\/JHC.S307962","volume":"Volume 8","author":"Y Jiang","year":"2021","unstructured":"Jiang Y, Han Q, Zhao H, Zhang J. The mechanisms of hbv-induced hepatocellular carcinoma. JHC. 2021;8:435\u201350. https:\/\/doi.org\/10.2147\/JHC.S307962.","journal-title":"JHC"},{"issue":"1","key":"13857_CR8","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/hep.510300109","volume":"30","author":"V Di Marco","year":"1999","unstructured":"Di Marco V, Iacono OL, Camm\u00e0 C, Vaccaro A, Giunta M, Martorana G, et al. The long-term course of chronic hepatitis b. Hepatology. 1999;30(1):257\u201364. https:\/\/doi.org\/10.1002\/hep.510300109.","journal-title":"Hepatology"},{"issue":"3","key":"13857_CR9","doi-asserted-by":"publisher","first-page":"250","DOI":"10.5539\/mas.v9n3p250","volume":"9","author":"MSF Chong","year":"2015","unstructured":"Chong MSF, Shahrill M, Crossley L, Madzvamuse A, et al. The stability analyses of the mathematical models of hepatitis c virus infection. MAS. 2015;9(3):250. https:\/\/doi.org\/10.5539\/mas.v9n3p250.","journal-title":"MAS"},{"key":"13857_CR10","doi-asserted-by":"crossref","unstructured":"Goyal A, Liao LE, Perelson AS. Within-host mathematical models of hepatitis b virus infection: past, present, and future, Current opinion in systems biology 18. 2019;27\u201335.","DOI":"10.1016\/j.coisb.2019.10.003"},{"issue":"1","key":"13857_CR11","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.jtbi.2010.10.024","volume":"269","author":"J Nakabayashi","year":"2011","unstructured":"Nakabayashi J, Sasaki A. A mathematical model of the intracellular replication and within host evolution of hepatitis type b virus: understanding the long time course of chronic hepatitis. J Theor Biol. 2011;269(1):318\u201329. https:\/\/doi.org\/10.1016\/j.jtbi.2010.10.024.","journal-title":"J Theor Biol"},{"key":"13857_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/475451","volume":"2014","author":"AV Kamyad","year":"2014","unstructured":"Kamyad AV, Akbari R, Heydari AA, Heydari A, et al. Mathematical modeling of transmission dynamics and optimal control of vaccination and treatment for hepatitis b virus. Comput Math Methods Med 2014. 2014;2014:1\u201315. https:\/\/doi.org\/10.1155\/2014\/475451.","journal-title":"Comput Math Methods Med 2014"},{"issue":"1\u20132","key":"13857_CR13","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s12190-018-01226-x","volume":"60","author":"P Yosyingyong","year":"2019","unstructured":"Yosyingyong P, Viriyapong R. Global stability and optimal control for a hepatitis b virus infection model with immune response and drug therapy. J Appl Math Comput. 2019;60(1\u20132):537\u201365. https:\/\/doi.org\/10.1007\/s12190-018-01226-x.","journal-title":"J Appl Math Comput"},{"issue":"5","key":"13857_CR14","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1053\/jhep.2001.28509","volume":"34","author":"SR Lewin","year":"2001","unstructured":"Lewin SR, Ribeiro RM, Walters T, Lau GK, Bowden S, Locarnini S, et al. Analysis of hepatitis b viral load decline under potent therapy: complex decay profiles observed. Hepatology. 2001;34(5):1012\u201320. https:\/\/doi.org\/10.1053\/jhep.2001.28509.","journal-title":"Hepatology"},{"key":"13857_CR15","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.mbs.2015.05.001","volume":"270","author":"Y Yang","year":"2015","unstructured":"Yang Y, Zou L, Ruan S. Global dynamics of a delayed within-host viral infection model with both virus-to-cell and cell-to-cell transmissions. Math Biosci. 2015;270:183\u201391. https:\/\/doi.org\/10.1016\/j.mbs.2015.05.001.","journal-title":"Math Biosci"},{"issue":"2","key":"13857_CR16","doi-asserted-by":"publisher","first-page":"283","DOI":"10.3934\/mbe.2009.6.283","volume":"6","author":"S Eikenberry","year":"2009","unstructured":"Eikenberry S, Hews S, Nagy JD, Kuang Y. The dynamics of a delay model of hepatitis b virus infection with logistic hepatocyte growth. Math Biosci Eng. 2009;6(2):283\u201399.","journal-title":"Math Biosci Eng"},{"issue":"2","key":"13857_CR17","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1080\/17513750701769873","volume":"2","author":"SA Gourley","year":"2008","unstructured":"Gourley SA, Kuang Y, Nagy JD. Dynamics of a delay differential equation model of hepatitis b virus infection. J Biol Dyn. 2008;2(2):140\u201353. https:\/\/doi.org\/10.1080\/17513750701769873.","journal-title":"J Biol Dyn"},{"issue":"9","key":"13857_CR18","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1016\/j.apm.2009.11.005","volume":"34","author":"Q Xie","year":"2010","unstructured":"Xie Q, Huang D, Zhang S, Cao J. Analysis of a viral infection model with delayed immune response. Appl Math Modell. 2010;34(9):2388\u201395. https:\/\/doi.org\/10.1016\/j.apm.2009.11.005.","journal-title":"Appl Math Modell"},{"issue":"3","key":"13857_CR19","doi-asserted-by":"publisher","first-page":"689","DOI":"10.3934\/mbe.2011.8.689","volume":"8","author":"B-Z Guo","year":"2011","unstructured":"Guo B-Z, Cai L-M. A note for the global stability of a delay differential equation of hepatitis b virus infection. Math Biosci Eng. 2011;8(3):689\u201394.","journal-title":"Math Biosci Eng"},{"issue":"9","key":"13857_CR20","doi-asserted-by":"publisher","first-page":"4398","DOI":"10.1073\/pnas.93.9.4398","volume":"93","author":"MA Nowak","year":"1996","unstructured":"Nowak MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC, McDade H. Viral dynamics in hepatitis b virus infection. Proc Natl Acad Sci USA. 1996;93(9):4398\u2013402. https:\/\/doi.org\/10.1073\/pnas.93.9.4398.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5255","key":"13857_CR21","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1126\/science.271.5255.1582","volume":"271","author":"AS Perelson","year":"1996","unstructured":"Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. Hiv-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science. 1996;271(5255):1582\u201386. https:\/\/doi.org\/10.1126\/science.271.5255.1582.","journal-title":"Science"},{"issue":"4","key":"13857_CR22","first-page":"689","volume":"245","author":"H Dahari","year":"2007","unstructured":"Dahari H, Lo A, Ribeiro RM, Perelson AS. Modeling hepatitis c virus kinetics under treatment using periodic and constant ribavirin dosing. J Theor Biol. 2007;245(4):689\u201397.","journal-title":"J Theor Biol"},{"key":"13857_CR23","doi-asserted-by":"publisher","first-page":"106469","DOI":"10.1016\/j.cmpb.2021.106469","volume":"212","author":"SA Tiomela","year":"2021","unstructured":"Tiomela SA, Mac\u00edas-D\u00edaz JE, Mvogo A. Computer simulation of the dynamics of a spatial susceptible-infected-recovered epidemic model with time delays in transmission and treatment. Comput Methods Programs Biomed. 2021;212:106469. https:\/\/doi.org\/10.1016\/j.cmpb.2021.106469.","journal-title":"Comput Methods Programs Biomed"},{"key":"13857_CR24","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jviromet.2019.01.014","volume":"266","author":"M Li","year":"2019","unstructured":"Li M, Zu J. The review of differential equation models of hbv infection dynamics. J Virol Methods. 2019;266:103\u201313. https:\/\/doi.org\/10.1016\/j.jviromet.2019.01.014.","journal-title":"J Virol Methods"},{"issue":"1","key":"13857_CR25","doi-asserted-by":"publisher","first-page":"578561","DOI":"10.1155\/2012\/578561","volume":"1","author":"NC Ch\u00ed","year":"2012","unstructured":"Ch\u00ed NC, AvilaVales E, Garc\u00eda Almeida G. Analysis of a hbv model with diffusion and time delay. J Appl Math. 2012;1(1):578561. https:\/\/doi.org\/10.1155\/2012\/578561.","journal-title":"J Appl Math"},{"issue":"4","key":"13857_CR26","doi-asserted-by":"publisher","first-page":"5207","DOI":"10.3934\/mbe.2024230","volume":"21","author":"T Khan","year":"2024","unstructured":"Khan T, Rihan FA, Ibrahim M, Li S, Alamri AM, AlQahtani SA. Modeling different infectious phases of hepatitis b with generalized saturated incidence: an analysis and control. MBE. 2024;21(4):5207\u201326. https:\/\/doi.org\/10.3934\/mbe.2024230.","journal-title":"MBE"},{"issue":"11","key":"13857_CR27","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1016\/j.aml.2009.06.004","volume":"22","author":"G Huang","year":"2009","unstructured":"Huang G, Ma W, Takeuchi Y. Global properties for virus dynamics model with Beddington\u2013DeAngelis functional response. Appl Math Lett. 2009;22(11):1690\u201393, zbl 1178.37125. https:\/\/doi.org\/10.1016\/j.aml.2009.06.004.","journal-title":"Appl Math Lett"},{"issue":"2","key":"13857_CR28","doi-asserted-by":"publisher","first-page":"177","DOI":"10.4236\/am.2012.32028","volume":"3","author":"H Ansari","year":"2012","unstructured":"Ansari H, Hesaaraki M. A with-in host dengue infection model with immune response and Beddington-DeAngelis incidence rate. AM. 2012;3(2):177\u201384. https:\/\/doi.org\/10.4236\/am.2012.32028.","journal-title":"AM"},{"issue":"3","key":"13857_CR29","doi-asserted-by":"publisher","first-page":"2250002","DOI":"10.1142\/S1793524522500024","volume":"15","author":"H Wang","year":"2022","unstructured":"Wang H, Tian X. Dynamics of a delayed within host model for dengue infection with immune response and Beddington\u2013DeAngelis incidence. Int J Biomath. 2022;15(3):2250002, zbl 1487.34134. https:\/\/doi.org\/10.1142\/S1793524522500024.","journal-title":"Int J Biomath"},{"key":"13857_CR30","doi-asserted-by":"publisher","unstructured":"Caldwell GW, Yan Z, Lang W, Masucci JA. The ic50 concept revisited, Current topics in medicinal chemistry. 2012;12(11):1282\u201390. https:\/\/doi.org\/10.2174\/156802612800672844.","DOI":"10.2174\/156802612800672844"},{"key":"13857_CR31","doi-asserted-by":"crossref","unstructured":"Ter Borg MJ, Hansen BE, Herrmann E, Zeuzem S, Cakaloglu Y, Karayalcin S, et al. Modelling of early viral kinetics and pegylated interferon-$$\\alpha$$2b pharmacokinetics in patients with hbeag-positive chronic hepatitis b. Antivir Ther. 2007;12(8):1285\u201394.","DOI":"10.1177\/135965350701200804"},{"issue":"1","key":"13857_CR32","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jtbi.2007.02.017","volume":"247","author":"SM Ciupe","year":"2007","unstructured":"Ciupe SM, Ribeiro RM, Nelson PW, Perelson AS. Modeling the mechanisms of acute hepatitis b virus infection. J Theor Biol. 2007;247(1):23\u201335. https:\/\/doi.org\/10.1016\/j.jtbi.2007.02.017.","journal-title":"J Theor Biol"},{"issue":"5","key":"13857_CR33","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1216\/RMJ-2008-38-5-1573","volume":"38","author":"L Min","year":"2008","unstructured":"Min L, Su Y, Kuang Y. Mathematical analysis of a basic virus infection model with application to hbv infection. Rocky Mt J Math. 2008;38(5):1573\u201385. https:\/\/doi.org\/10.1216\/RMJ-2008-38-5-1573.","journal-title":"Rocky Mt J Math"},{"issue":"2","key":"13857_CR34","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/hep.510280206","volume":"28","author":"AR Crawford","year":"1998","unstructured":"Crawford AR, Lin X-Z, Crawford JM. The normal adult human liver biopsy: a quantitative reference standard. Hepatology. 1998;28(2):323\u201331. https:\/\/doi.org\/10.1002\/hep.510280206.","journal-title":"Hepatology"},{"key":"13857_CR35","doi-asserted-by":"crossref","unstructured":"Barril G, Quiroga J, Sanz P, Selgas R, Carre\u00f1o V. Pegylated interferon-$$\\alpha$$2a kinetics during experimental hd: impact of permeability and pore size of dialyzer. Hemodial Int. 2003;7(1):73\u2013104.","DOI":"10.1046\/j.1492-7535.2003.01255.x"},{"key":"13857_CR36","unstructured":"Gerber M. Synthesis and transdermal penetration of selected lamivudine derivatives, Ph.D. thesis, 2007, North-West University."},{"key":"13857_CR37","doi-asserted-by":"publisher","unstructured":"Lu P-X, Huang H, Yuan J, Zhao F, Chen Z-Y, Zhang Q, et al. Decreases in molecular diffusion, perfusion fraction and perfusion-related diffusion in fibrotic livers: a prospective clinical intravoxel incoherent motion mr imaging study. PLoS One. 2014;9(12):e113846. https:\/\/doi.org\/10.1371\/journal.pone.0113846.","DOI":"10.1371\/journal.pone.0113846"},{"key":"13857_CR38","doi-asserted-by":"publisher","DOI":"10.4324\/9780203833582","volume-title":"Cell movements: from molecules to motility","author":"D Bray","year":"2000","unstructured":"Bray D. Cell movements: from molecules to motility. Garland Science; 2000."},{"key":"13857_CR39","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3354\/meps089103","volume":"89","author":"AG Murray","year":"1992","unstructured":"Murray AG, Jackson GA. Viral dynamics: a model of the effects of size shape, motion and abundance of single-celled olanktonic organisms and other particles. Mar Ecol Prog Ser. 1992;89:103\u201316. https:\/\/doi.org\/10.3354\/meps089103.","journal-title":"Mar Ecol Prog Ser"},{"issue":"1","key":"13857_CR40","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/hep.20738","volume":"42","author":"V-A Sypsa","year":"2005","unstructured":"Sypsa V-A, Mimidis K, Tassopoulos NC, Chrysagis D, Vassiliadis T, Moulakakis A, et al. A viral kinetic study using pegylated interferon alfa-2b and\/or lamivudine in patients with chronic hepatitis B\/HBeAg negative. Hepatology. 2005;42(1):77\u201385. https:\/\/doi.org\/10.1002\/hep.20738.","journal-title":"Hepatology"},{"key":"13857_CR41","doi-asserted-by":"crossref","unstructured":"Radwanski E, Perentesis G, Jacobs S, Oden E, Affrime M, Symchowicz S, et al. Pharmacokinetics of interferon $$\\alpha$$-2b in healthy volunteers. J Clin Pharmacol. 1987;27(5):432\u201335.","DOI":"10.1002\/j.1552-4604.1987.tb03044.x"},{"key":"13857_CR42","doi-asserted-by":"crossref","unstructured":"Gupta SK, Pittenger AL, Swan SK, Marbury TC, Tobillo E, Batra V, et al. Single-dose pharmacokinetics and safety of pegylated interferon-$$\\alpha$$2b in patients with chronic renal dysfunction. J Clin Pharmacol. 2002;42(10):1109\u201315.","DOI":"10.1177\/009127002237996"},{"key":"13857_CR43","doi-asserted-by":"crossref","unstructured":"Gu C-Q, Li J-W, Chao F-H. Inhibition of hepatitis b virus by d-fraction from grifola frondosa: synergistic effect of combination with interferon-$$\\alpha$$ in hepg2 2.2. 15. Antiviral Res. 2006;72(2):162\u201365.","DOI":"10.1016\/j.antiviral.2006.05.011"},{"issue":"11","key":"13857_CR44","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s00228-007-0337-x","volume":"63","author":"X Panhard","year":"2007","unstructured":"Panhard X, Legrand M, Taburet A-M, Diquet B, Goujard F, Mentr\u00e9 C-AS, et al. Group, population pharmacokinetic analysisof lamivudine, stavudine and zidovudine in controlled hiv-infected patients on haart. Eur J Clin Pharmacol. 2007;63(11):1019\u201329. https:\/\/doi.org\/10.1007\/s00228-007-0337-x.","journal-title":"Eur J Clin Pharmacol"},{"issue":"10","key":"13857_CR45","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1016\/j.clinthera.2013.07.431","volume":"35","author":"X Li","year":"2013","unstructured":"Li X, Liu B, Sun Y, Chen H, Chen H, Zhang H, et al. Single-dose pharmacokinetic properties, bioavailability, and tolerability of two lamivudine 100-mg tablet formulations: a randomized crossover study in healthy Chinese male subjects. Clin Ther. 2013;35(10):1546\u201356. https:\/\/doi.org\/10.1016\/j.clinthera.2013.07.431.","journal-title":"Clin Ther"},{"issue":"1","key":"13857_CR46","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2165\/00003495-199958010-00015","volume":"58","author":"B Jarvis","year":"1999","unstructured":"Jarvis B, Faulds D. Lamivudine: a review of its therapeutic potential in chronic hepatitis b. Drugs. 1999;58(1):101\u201341. https:\/\/doi.org\/10.2165\/00003495-199958010-00015.","journal-title":"Drugs"},{"issue":"4","key":"13857_CR47","doi-asserted-by":"publisher","first-page":"657","DOI":"10.2165\/00003495-199753040-00008","volume":"53","author":"CM Perry","year":"1997","unstructured":"Perry CM, Faulds D. Lamivudine: a review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of hiv infection. Drugs. 1997;53(4):657\u201380. https:\/\/doi.org\/10.2165\/00003495-199753040-00008.","journal-title":"Drugs"},{"issue":"1","key":"13857_CR48","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/hep.21657","volume":"46","author":"H Dahari","year":"2007","unstructured":"Dahari H, Ribeiro RM, Perelson AS. Triphasic decline of hepatitis c virus rna during antiviral therapy. Hepatology. 2007;46(1):16\u201321. https:\/\/doi.org\/10.1002\/hep.21657.","journal-title":"Hepatology"},{"issue":"3","key":"13857_CR49","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1002\/hep.23190","volume":"50","author":"AS Lok","year":"2009","unstructured":"Lok AS, McMahon BJ. Chronic hepatitis b: update 2009. Hepatology. 2009;50(3):661\u201362.","journal-title":"Hepatology"},{"issue":"14","key":"13857_CR50","doi-asserted-by":"publisher","first-page":"5388","DOI":"10.1002\/mma.5085","volume":"41","author":"D Zhu","year":"2018","unstructured":"Zhu D, Ren J, Zhu H. Spatial-temporal basic reproduction number and dynamics for a dengue disease diffusion model, mathematical Methods in the applied sciences. Math Methods Appl Sci. 2018;41(14):5388\u2013403. https:\/\/doi.org\/10.1002\/mma.5085.","journal-title":"Math Methods Appl Sci"},{"issue":"1","key":"13857_CR51","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1137\/18M1182243","volume":"79","author":"P Magal","year":"2019","unstructured":"Magal P, Webb GF, Wu Y. On the basic reproduction number of reaction-diffusion epidemic models. SIAM J Appl Math. 2019;79(1):284\u2013304. https:\/\/doi.org\/10.1137\/18M1182243.","journal-title":"SIAM J Appl Math"},{"key":"13857_CR52","doi-asserted-by":"crossref","unstructured":"Diekmann O, Heesterbeek J, Metz J. On the definition and the computation of the basic reproduction ratio $$r_0$$ in models for infectious diseases in heterogeneous populations. J Math Biol. 1990;28(4):365\u201382.","DOI":"10.1007\/BF00178324"},{"issue":"47","key":"13857_CR53","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1098\/rsif.2009.0386","volume":"7","author":"O Diekmann","year":"2010","unstructured":"Diekmann O, Heesterbeek J, Roberts M. The construction of next-generation matrices for compartmental epidemic models. J R Soc Interface. 2010;7(47):873\u201385. https:\/\/doi.org\/10.1098\/rsif.2009.0386.","journal-title":"J R Soc Interface"},{"key":"13857_CR54","volume-title":"Pharmacology: drug actions and reactions","author":"RR Levine","year":"2000","unstructured":"Levine RR, Walsh CT, Schwartz-Bloom RD. Pharmacology: drug actions and reactions. CRC Press; 2000."},{"issue":"6","key":"13857_CR55","first-page":"348","volume":"13","author":"MG Peters","year":"2017","unstructured":"Peters MG, Locarnini S. New direct-acting antiviral agents and immunomodulators for hepatitis b virus infection. Gastroenterol Hepatol (New York). 2017;13(6):348.","journal-title":"Gastroenterol Hepatol (N Y)"},{"issue":"2","key":"13857_CR56","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.jhep.2015.02.037","volume":"63","author":"EJ Gane","year":"2015","unstructured":"Gane EJ, Lim Y-S, Gordon SC, Visvanathan K, Sicard E, Fedorak RN, et al. The oral toll-like receptor-7 agonist gs-9620 in patients with chronic hepatitis b virus infection. J Hepatol. 2015;63(2):320\u201328. https:\/\/doi.org\/10.1016\/j.jhep.2015.02.037.","journal-title":"J Hepatol"},{"key":"13857_CR57","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ctrv.2017.05.003","volume":"57","author":"JC Hassel","year":"2017","unstructured":"Hassel JC, Heinzerling L, Aberle J, B\u00e4hr O, Eigentler TK, Grimm M-O, et al. Combined immune checkpoint blockade (anti-pd-1\/anti-ctla-4): evaluation and management of adverse drug reactions. Cancer Treat Rev. 2017;57:36\u201349. https:\/\/doi.org\/10.1016\/j.ctrv.2017.05.003.","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"13857_CR58","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1128\/AAC.35.2.394","volume":"35","author":"T Yokota","year":"1991","unstructured":"Yokota T, Mochizuki S, Konno K, Mori S, Shigeta S, De Clercq E. Inhibitory effects of selected antiviral compounds on human hepatitis b virus dna synthesis. Antimicrob Agents Chemother. 1991;35(2):394\u201397. https:\/\/doi.org\/10.1128\/AAC.35.2.394.","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"13857_CR59","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1111\/j.1572-0241.2002.05819.x","volume":"97","author":"GV Papatheodoridis","year":"2002","unstructured":"Papatheodoridis GV, Dimou E, Papadimitropoulos V. Nucleoside analogues for chronic hepatitis b: antiviral efficacy and viral resistance. Am J Gastroenterol. 2002;97(7):1618\u201328. https:\/\/doi.org\/10.1111\/j.1572-0241.2002.05819.x.","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"13857_CR60","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.cld.2004.02.012","volume":"8","author":"DJ Quan","year":"2004","unstructured":"Quan DJ, Peters MG. Antiviral therapy: nucleotide and nucleoside analogs, clinics in liver disease. Clin Liver Dis. 2004;8(2):371\u201385. https:\/\/doi.org\/10.1016\/j.cld.2004.02.012.","journal-title":"Clin Liver Dis"},{"issue":"6","key":"13857_CR61","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1586\/17474124.2014.909724","volume":"8","author":"AO-S Lo","year":"2014","unstructured":"Lo AO-S, Wong GL-H. Current developments in nucleoside\/nucleotide analogues for hepatitis b, expert review of gastroenterology & hepatology. Expert Rev Gastroenterol Hepatol. 2014;8(6):607\u201322. https:\/\/doi.org\/10.1586\/17474124.2014.909724.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"2","key":"13857_CR62","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s40262-012-0027-4","volume":"52","author":"M Dostalek","year":"2013","unstructured":"Dostalek M, Gardner I, Gurbaxani BM, Rose RH, Chetty M. Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies. Clin Pharmacokinet. 2013;52(2):83\u2013124. https:\/\/doi.org\/10.1007\/s40262-012-0027-4.","journal-title":"Clin Pharmacokinet"},{"issue":"17","key":"13857_CR63","doi-asserted-by":"publisher","first-page":"3963","DOI":"10.1111\/bph.12604","volume":"171","author":"DM Moss","year":"2014","unstructured":"Moss DM, Siccardi M. Optimizing nanomedicine pharmacokinetics using physiologically based pharmacokinetics modelling. Br J Pharmacol. 2014;171(17):3963\u201379. https:\/\/doi.org\/10.1111\/bph.12604.","journal-title":"Br J Pharmacol"},{"issue":"3","key":"13857_CR64","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s10928-005-9002-0","volume":"33","author":"C Csajka","year":"2006","unstructured":"Csajka C, Verotta D. Pharmacokinetic\u2013pharmacodynamic modelling: history and perspectives. J Pharmacokinet Pharmacodyn. 2006;33(3):227\u201379. https:\/\/doi.org\/10.1007\/s10928-005-9002-0.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"3","key":"13857_CR65","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1006\/jtbi.1997.0438","volume":"194","author":"D Austin","year":"1998","unstructured":"Austin D, White N, Anderson R. The dynamics of drug action on the within-host population growth of infectious agents: melding pharmacokinetics with pathogen population dynamics. J Theor Biol. 1998;194(3):313\u201339. https:\/\/doi.org\/10.1006\/jtbi.1997.0438.","journal-title":"J Theor Biol"},{"issue":"9","key":"13857_CR66","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1111\/j.1365-2036.2005.02453.x","volume":"21","author":"M van Zonneveld","year":"2005","unstructured":"van Zonneveld M, Flink HJ, Verhey E, Senturk H, Zeuzem S, Akarca US, et al. The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis b: predictive factors for dose reduction and treatment discontinuation. Aliment Pharmacol Ther. 2005;21(9):1163\u201371. https:\/\/doi.org\/10.1111\/j.1365-2036.2005.02453.x.","journal-title":"Aliment Pharmacol Ther"},{"issue":"9286","key":"13857_CR67","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","volume":"358","author":"MP Manns","year":"2001","unstructured":"Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis c: a randomised trial. Lancet. 2001;358(9286):958\u201365. https:\/\/doi.org\/10.1016\/S0140-6736(01)06102-5.","journal-title":"Lancet"},{"issue":"7","key":"13857_CR68","first-page":"854","volume":"18","author":"Y-F Liaw","year":"2003","unstructured":"Liaw Y-F. Hepatitis b virus resistance to lamivudine and other therapies. J Gastroen Hepatol. 2003;18(7):854\u201359.","journal-title":"J Gastroen Hepatol"},{"issue":"5","key":"13857_CR69","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1177\/135965350400900522","volume":"9","author":"S Locarnini","year":"2004","unstructured":"Locarnini S. Drug resistance in hepatitis b viruses, antiviral therapy. Antivir Ther. 2004;9(5):679\u201393. https:\/\/doi.org\/10.1177\/135965350400900522.","journal-title":"Antivir Ther"},{"issue":"1","key":"13857_CR70","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jhazmat.2008.01.052","volume":"158","author":"MI El-Khaiary","year":"2008","unstructured":"El-Khaiary MI. Least-squares regression of adsorption equilibrium data: comparing the options. J Hazard Mater. 2008;158(1):73\u201387. https:\/\/doi.org\/10.1016\/j.jhazmat.2008.01.052.","journal-title":"J Hazard Mater"},{"key":"13857_CR71","volume-title":"A practical approach for machine learning and deep learning algorithms: tools and techniques using MATLAB and Python","author":"AK Pandey","year":"2019","unstructured":"Pandey AK, Rathore PS, Balamurugan S. A practical approach for machine learning and deep learning algorithms: tools and techniques using MATLAB and Python. BPB Publications; 2019."},{"issue":"2","key":"13857_CR72","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S0168-8278(02)00113-7","volume":"37","author":"LMM Wolters","year":"2002","unstructured":"Wolters LMM, Hansen BE, Niesters HGM, Levi-Drummer RS, Neumann AU, Schalm SW, et al. The influence of baseline characteristics on viral dynamic parameters in chronic hepatitis b patients treated with lamivudine. J Hepatol. 2002;37(2):253\u201358.","journal-title":"J Hepatol"},{"issue":"4","key":"13857_CR73","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1053\/gast.1997.v113.pm9322520","volume":"113","author":"F Nevens","year":"1997","unstructured":"Nevens F, Main J, Honkoop P, Tyrrell DL, Barber J, Sullivan MT, et al. Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study. Gastroenterology. 1997;113(4):1258\u201363. https:\/\/doi.org\/10.1053\/gast.1997.v113.pm9322520.","journal-title":"Gastroenterology"},{"issue":"6","key":"13857_CR74","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1007\/s12072-020-10099-x","volume":"14","author":"J Liu","year":"2020","unstructured":"Liu J, Wang T, Zhang W, Cheng Y, He Q, Wang F-S. Effect of combination treatment based on interferon and nucleos (t) ide analogues on functional cure of chronic hepatitis b: a systematic review and meta-analysis. Hepatol Int. 2020;14(6):958\u201372. https:\/\/doi.org\/10.1007\/s12072-020-10099-x.","journal-title":"Hepatol Int"},{"issue":"1","key":"13857_CR75","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S1089-3261(02)00063-6","volume":"7","author":"TJ Layden","year":"2003","unstructured":"Layden TJ, Layden JE, Ribeiro RM, Perelson AS. Mathematical modeling of viral kinetics: a tool to understand and optimize therapy, clinics in liver disease. Clin Liver Dis. 2003;7(1):163\u201378. https:\/\/doi.org\/10.1016\/S1089-3261(02)00063-6.","journal-title":"Clin Liver Dis"},{"issue":"19","key":"13857_CR76","doi-asserted-by":"publisher","first-page":"5730","DOI":"10.3748\/wjg.v20.i19.5730","volume":"20","author":"E-Q Chen","year":"2014","unstructured":"Chen E-Q, Tang H. Optimization therapy for the treatment of chronic hepatitis b. World J Gastroenterol: WJG. 2014;20(19):5730. https:\/\/doi.org\/10.3748\/wjg.v20.i19.5730.","journal-title":"World J Gastroenterol: WJG"},{"issue":"6","key":"13857_CR77","doi-asserted-by":"publisher","first-page":"062215","DOI":"10.1103\/PhysRevE.102.062215","volume":"102","author":"Q Zheng","year":"2020","unstructured":"Zheng Q, Shen J, Xu Y. Turing instability in the reaction-diffusion network. Phys Rev E. 2020;102(6):062215. https:\/\/doi.org\/10.1103\/PhysRevE.102.062215.","journal-title":"Phys Rev E"},{"key":"13857_CR78","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.na.2013.03.001","volume":"85","author":"Y Lv","year":"2013","unstructured":"Lv Y, Yuan R, Pei Y. Turing pattern formation in a three species model with generalist predator and cross-diffusion, nonlinear analysis: theory. Nonlinear Anal Theory Methods Appl. 2013;85:214\u201332. https:\/\/doi.org\/10.1016\/j.na.2013.03.001.","journal-title":"Nonlinear Anal Theory Methods Appl"},{"issue":"2","key":"13857_CR79","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/0898-1221(84)90043-9","volume":"10","author":"J Cash","year":"1984","unstructured":"Cash J. Diagonally implicit runge-kutta formulae for the numerical integration of nonlinear two-point boundary value problems. Comput Math Appl. 1984;10(2):123\u201337. https:\/\/doi.org\/10.1016\/0898-1221(84)90043-9.","journal-title":"Comput Math Appl"},{"key":"13857_CR80","doi-asserted-by":"publisher","unstructured":"Ismail F, Al-Khasawneh RA, Suleiman M, et al. Numerical treatment of delay differential equations by runge-kutta method using hermite interpolation. Matematika. 2002;18(2):79\u201390. https:\/\/doi.org\/10.11113\/matematika.v18.n.121","DOI":"10.11113\/matematika.v18.n.121"},{"issue":"11","key":"13857_CR81","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1517\/13543780903241599","volume":"18","author":"I Carey","year":"2009","unstructured":"Carey I, Harrison PM. Monotherapy versus combination therapy for the treatment of chronic hepatitis b. Expert Opin Investigational Drugs. 2009;18(11):1655\u201366. https:\/\/doi.org\/10.1517\/13543780903241599.","journal-title":"Expert Opin Investigational Drugs"},{"issue":"1","key":"13857_CR82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12985-018-1050-3","volume":"15","author":"A Luo","year":"2018","unstructured":"Luo A, Jiang X, Ren H. Lamivudine plus tenofovir combination therapy versus lamivudine monotherapy for hbv\/hiv coinfection: a meta-analysis. Virol J. 2018;15(1):1\u20139. https:\/\/doi.org\/10.1186\/s12985-018-1050-3.","journal-title":"Virol J"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-13857-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13857-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13857-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:33:01Z","timestamp":1789684381000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-13857-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":82,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["13857"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-13857-8","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]},"assertion":[{"value":"25 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study does not involve human participants, human data, or human biological samples. All data used in this work are obtained from published literature. Therefore, ethical approval from an Institutional Review Board (IRB) or ethics committee was not required according to applicable regulations. This study was conducted in accordance with relevant guidelines and regulations.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1674"}}